Research progress of bone sialogin in malignant tumors

doi:10.3760/cma.j.issn.1007-1245.2023.14.004

Abstract

Abstract:

Bone sialoprotein (BSP) is a non-collagenous phosphorylated glycoprotein secreted by bone matrix and tumor cells, and exists in extracellular matrix (ECM). By binding to integrin avβ3, it can mediate the adhesion between tumor cells and ECM, promote the degradation of ECM, participate in angiogenesis and humoral immunity, etc. It plays a key role in the process of malignant tumor proliferation, invasion, and metastasis, and is considered as a new tumor marker. This paper summarizes the biological characteristics of BSP and the recent studies on the correlation between BSP and malignant tumors, and evaluates the clinical significance of BSP in the early diagnosis, efficacy evaluation, and prognosis monitoring of malignant tumors.

Key words:

Malignant tumors, Bone sialoprotein, Integrin avβ3, Progress

摘要：

骨唾液酸蛋白（BSP）是由骨基质和肿瘤细胞分泌，存在于细胞外基质（ECM）中的一种非胶原磷酸化糖蛋白，通过与整合素avβ3结合，可以介导肿瘤细胞与ECM的黏附作用、促进ECM的降解、参与血管生成和体液免疫等，在恶性肿瘤增殖、侵袭和转移过程中起着关键作用，被认为是一种新的肿瘤标志物。本文概述了BSP的生物学特性及近年来BSP与恶性肿瘤的相关性研究，进而评估其在恶性肿瘤早期诊断、疗效评价和预后监测的临床意义。

关键词:

恶性肿瘤, 骨唾液酸蛋白, 整合素avβ3, 进展

Li Zhenlian, Kang Xiaoling, Li Huibin, Liao Yanxia, Peng Dayun, Gao Hongyi.

Research progress of bone sialogin in malignant tumors [J]. International Medicine and Health Guidance News, 2023, 29(14): 1940-1943.

李振连康小玲李辉斌廖燕霞彭大云郜红艺.

骨唾液酸蛋白在恶性肿瘤中的研究进展 [J]. 国际医药卫生导报, 2023, 29(14): 1940-1943.

References

[1] Bellahcène A,Castronovo V,Ogbureke KU,et al.Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer[J].Nat Rev Cancer,2008,8(3):212-226.DOI:10.1038/nrc2345.
[2] Keller F,Bruch R,Clauder F,et al.Extracellular matrix components regulate bone sialoprotein expression in MDA-MB-231 breast cancer cells[J].Cells,2021,10(6):1304.DOI:10.3390/cells10061304.
[3] Wang L,Song L,Li J,et al.Bone sialoprotein-αvβ3 integrin axis promotes breast cancer metastasis to the bone[J].Cancer Sci,2019,110(10):3157-3172.DOI:10.1111/cas.14172.
[4] Liu B,Xu M,Guo Z,et al.Interleukin-8 promotes prostate cancer bone metastasis through upregulation of bone sialoprotein[J].Oncol Lett,2019,17(5):4607-4613.DOI:10.3892/ol.2019.10138.
[5] Maaroufi A,Khadem-Ansari MH,Khalkhali HR,et al.Serum levels of bone sialoprotein, osteopontin, and β2-microglobulin in stage I of multiple myeloma[J].J Cancer Res Ther,2020,16(1):98-101.DOI:10.4103/jcrt.JCRT_666_16.
[6] Chen Y,Qin Y,Dai M,et al.IBSP, a potential recurrence biomarker, promotes the progression of colorectal cancer via Fyn/β-catenin signaling pathway[J].Cancer Med,2021,10(12):4030-4045.DOI:10.1002/cam4.3959.
[7] Xu T,Qin R,Zhou J,et al.High bone sialoprotein (BSP) expression correlates with increased tumor grade and predicts a poorer prognosis of high-grade glioma patients[J].PLoS One,2012,7(10):e48415.DOI:10.1371/journal.pone.
[8] Wu G,Guo JJ,Ma ZY,et al.Correlation between calcification and bone sialoprotein and osteopontin in papillary thyroid carcinoma[J].Int J Clin Exp Pathol,2015,8(2):2010-2017.
[9] Wang M,Liu B,Li D,et al.Upregulation of IBSP expression predicts poor prognosis in patients with esophageal squamous cell carcinoma[J].Front Oncol,2019,9:1117.DOI:10.3389/fonc.2019.01117.
[10] He JJ,Zhi K,Liu GF.Predictive value of serum bone sialoprotein in patients with bone metastasis of non-small cell lung cancer[J].Onkologie,2011,34(11):584-588.DOI:10.1159/000334058.
[11] Loosen SH,Hoening P,Puethe N,et al.Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma[J].Sci Rep,2019,9(1):1489.DOI:10.1038/s41598-018-38352-2.
[12] Lamour V,Nokin MJ,Henry A,et al.Les protéines SIBLING - Outils moléculaires de la progression tumorale et de l'angiogenèse [SIBLING proteins: molecular tools for tumor progression and angiogenesis][J].Med Sci (Paris),2013,29(11):1018-1025.DOI:10.1051/medsci/20132911019.
[13] Ganss B,Kim RH,Sodek J.Bone sialoprotein[J].Crit Rev Oral Biol Med,1999,10(1):79-98.DOI:10.1177/10454411990100010401.
[14] Xu L,Zhang Z,Sun X,et al.Glycosylation status of bone sialoprotein and its role in mineralization[J].Exp Cell Res,2017,360(2):413-420.DOI:10.1016/j.yexcr.2017.09.034.
[15] Bellahcène A,Bonjean K,Fohr B,et al.Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis[J].Circ Res,2000,86(8):885-891.DOI:10.1161/01.res.86.8.885.
[16] Muruganandan S,Ionescu AM,Sinal CJ.At the crossroads of the adipocyte and osteoclast differentiation programs: future therapeutic perspectives[J].Int J Mol Sci,2020,21(7):2277.DOI:10.3390/ijms21072277.
[17] Hanahan D.Hallmarks of cancer: new dimensions[J].Cancer Discov,2022,12(1):31-46.DOI:10.1158/2159-8290.CD-21-1059.
[18] Hanahan D,Weinberg RA.Hallmarks of cancer: the next generation[J].Cell,2011,144(5):646-674.DOI:10.1016/j.cell.2011.02.013.
[19] Liu W,Deng Y,Li Z,et al.Cancer evo-dev: a theory of inflammation-induced oncogenesis[J].Front Immunol,2021,12:768098.DOI:10.3389/fimmu.2021.768098.
[20] Sökeland G,Schumacher U.The functional role of integrins during intra- and extravasation within the metastatic cascade[J].Mol Cancer,2019,18(1):12.DOI:10.1186/s12943-018-0937-3.
[21] Wu JS,Jiang J,Chen BJ,et al.Plasticity of cancer cell invasion: patterns and mechanisms[J].Transl Oncol,2021,14(1):100899.DOI:10.1016/j.tranon.2020.100899.
[22] Anunobi CC,Koli K,Saxena G,et al.Expression of the SIBLINGs and their MMP partners in human benign and malignant prostate neoplasms[J].Oncotarget,2016,7(30):48038-48049.DOI:10.18632/oncotarget.10110.
[23] Rivera LB,Bergers G.Intertwined regulation of angiogenesis and immunity by myeloid cells[J].Trends Immunol,2015,36(4):240-249.DOI:10.1016/j.it.2015.02.005.
[24] Strilic B,Offermanns S.Intravascular survival and extravasation of tumor cells[J].Cancer Cell,2017,32(3):282-293.DOI:10.1016/j.ccell.2017.07.001.
[25] El-Kenawi A,Hänggi K,Ruffell B.The immune microenvironment and cancer metastasis[J].Cold Spring Harb Perspect Med,2020,10(4):a037424.DOI:10.1101/cshperspect.a037424.
[26] Nam JS,Suchar AM,Kang MJ,et al.Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer[J].Cancer Res,2006,66(12):6327-6335.DOI:10.1158/0008-5472.CAN-06-0068.
[27] López-Soto A,Gonzalez S,Smyth MJ,et al.Control of metastasis by NK cells[J].Cancer Cell,2017,32(2):135-154.DOI:10.1016/j.ccell.2017.06.009.
[28] Bellahcène A,Merville MP,Castronovo V.Expression of bone sialoprotein, a bone matrix protein, in human breast cancer[J].Cancer Res,1994,54(11):2823-2826.
[29] Hardy E,Fernandez-Patron C.Destroy to rebuild: the connection between bone tissue remodeling and matrix metalloproteinases[J].Front Physiol,2020,11:47.DOI:10.3389/fphys.2020.00047.
[30] Woitge HW,Pecherstorfer M,Horn E,et al.Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma[J].Br J Cancer,2001,84(3):344-351.DOI:10.1054/bjoc.2000.1614.
[31] Fares J,Fares MY,Khachfe HH,et al.Molecular principles of metastasis: a hallmark of cancer revisited[J].Signal Transduct Target Ther,2020,5(1):28.DOI:10.1038/s41392-020-0134-x.